A Community Pharmacist's Guide to Oral COVID-19 Antivirals.

Tyler C Melton, Brandon K Hawkins
{"title":"A Community Pharmacist's Guide to Oral COVID-19 Antivirals.","authors":"Tyler C Melton,&nbsp;Brandon K Hawkins","doi":"10.24926/iip.v13i3.4961","DOIUrl":null,"url":null,"abstract":"<p><p>The recent approval of novel, oral antivirals for the treatment of COVID-19 has significantly altered the outpatient management of patients diagnosed with COVID-19. From a community pharmacy perspective, the two treatment options for mild to moderate COVID-19 are Paxlovid™ (nirmatrelvir/ritonavir) and Lagevrio™ (molnupiravir). While the availability of these antivirals has expanded community pharmacists' capability to provide care for patients diagnosed with COVID-19, many community pharmacists may struggle to effectively operationalize these agents in practice. This commentary provides a review of Paxlovid™ and Lagevrio™ clarifying the differences between each medication and their respective places in therapy, as well as suggestions and best-practices to operationalize the provision of these services in community pharmacies. These considerations are necessary to support and inform community pharmacy practice when providing oral COVID-19 antiviral therapy.</p>","PeriodicalId":13646,"journal":{"name":"Innovations in Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/b1/21550417-13-03-4961.PMC9815871.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innovations in Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24926/iip.v13i3.4961","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The recent approval of novel, oral antivirals for the treatment of COVID-19 has significantly altered the outpatient management of patients diagnosed with COVID-19. From a community pharmacy perspective, the two treatment options for mild to moderate COVID-19 are Paxlovid™ (nirmatrelvir/ritonavir) and Lagevrio™ (molnupiravir). While the availability of these antivirals has expanded community pharmacists' capability to provide care for patients diagnosed with COVID-19, many community pharmacists may struggle to effectively operationalize these agents in practice. This commentary provides a review of Paxlovid™ and Lagevrio™ clarifying the differences between each medication and their respective places in therapy, as well as suggestions and best-practices to operationalize the provision of these services in community pharmacies. These considerations are necessary to support and inform community pharmacy practice when providing oral COVID-19 antiviral therapy.

Abstract Image

Abstract Image

社区药剂师口服COVID-19抗病毒药物指南。
最近批准用于治疗COVID-19的新型口服抗病毒药物显著改变了COVID-19患者的门诊管理。从社区药房的角度来看,轻至中度COVID-19的两种治疗选择是Paxlovid™(nirmatrelvir/ritonavir)和Lagevrio™(molnupiravir)。虽然这些抗病毒药物的可用性扩大了社区药剂师为COVID-19确诊患者提供护理的能力,但许多社区药剂师在实践中可能难以有效地使用这些药物。本评论对Paxlovid™和Lagevrio™进行了回顾,阐明了每种药物之间的差异及其各自在治疗中的作用,以及在社区药房提供这些服务的建议和最佳做法。在提供口服COVID-19抗病毒治疗时,这些考虑对于支持和告知社区药房实践是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信